|Bid||9.10 x 1100|
|Ask||11.36 x 1000|
|Day's range||9.30 - 9.76|
|52-week range||8.06 - 18.68|
|Beta (5Y monthly)||0.08|
|PE ratio (TTM)||N/A|
|Earnings date||03 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||27.00|
CAMBRIDGE, Mass. & MONTREAL, March 14, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR Annual Meeting, held April 14-19, 2023, in Orlando, Florida. An AACR assigned
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass. & MONTREAL, February 28, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022.